Zacks Research Comments on AbbVie’s Q1 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Stock analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for AbbVie in a research report issued to clients and investors on Thursday, March 13th. Zacks Research analyst S. Ganoria now expects that the company will post earnings per share of $2.88 for the quarter, up from their previous forecast of $2.87. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q2 2026 earnings at $3.33 EPS, Q3 2026 earnings at $3.63 EPS, Q4 2026 earnings at $3.80 EPS, FY2026 earnings at $13.64 EPS and FY2027 earnings at $14.89 EPS.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period last year, the business earned $2.79 earnings per share.

Other research analysts have also recently issued reports about the company. UBS Group boosted their target price on AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Raymond James reiterated an “outperform” rating and issued a $220.00 price target (up previously from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Daiwa America lowered AbbVie from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 5th. Truist Financial raised their price target on shares of AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Bank of America raised their price objective on shares of AbbVie from $200.00 to $223.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $211.45.

AbbVie Price Performance

NYSE:ABBV opened at $211.90 on Monday. AbbVie has a 52 week low of $153.58 and a 52 week high of $218.66. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The company has a market capitalization of $374.07 billion, a P/E ratio of 88.29, a P/E/G ratio of 1.62 and a beta of 0.61. The stock’s fifty day moving average is $191.09 and its two-hundred day moving average is $188.05.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.10%. AbbVie’s dividend payout ratio (DPR) is presently 273.33%.

Insider Buying and Selling

In other AbbVie news, EVP Timothy J. Richmond sold 29,917 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the sale, the executive vice president now owns 44,284 shares of the company’s stock, valued at $8,985,223.60. The trade was a 40.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Kevin K. Buckbee sold 18,944 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the sale, the senior vice president now directly owns 11,496 shares in the company, valued at $2,338,401.36. The trade was a 62.23 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 54,639 shares of company stock valued at $11,067,025. 0.25% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Lansforsakringar Fondforvaltning AB publ purchased a new position in shares of AbbVie during the 4th quarter valued at $104,347,000. PKO Investment Management Joint Stock Co purchased a new position in AbbVie in the fourth quarter worth $2,399,000. Northstar Financial Companies Inc. purchased a new position in AbbVie in the fourth quarter worth $1,219,000. Centaurus Financial Inc. grew its position in AbbVie by 2.3% in the fourth quarter. Centaurus Financial Inc. now owns 8,507 shares of the company’s stock worth $1,512,000 after acquiring an additional 188 shares in the last quarter. Finally, Lighthouse Financial LLC purchased a new position in AbbVie in the fourth quarter worth $700,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.